Aktuellt
SENASTE
Redeye comments on Spago’s Q3 2022 report, and we estimate that the company is closing in on wrapping up its phase I SAGOPIX-01 trial with contrast agent SpagoPix (SN132D) and initiating a phase I/IIa trial with radionuclide drug candidate Tumorad (177Lu-SN201). We review our estimates and make some adjustments to our valuation.
LÄS MER
